Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide
Reji Thomas, Mesut Çetin, Glen B. Baker, Serdar Murat Dursun
Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology October 30, 2016 DOI: 10.5455/bcp.20161027122045 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression Esketamine |
| Citations | 6 |
Abstract
-
Citations in the library
Cited by 4
- Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review Cureus August 21, 2021
- An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine Current Topics in Medicinal Chemistry January 31, 2020
- Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use. Frontiers in Psychology March 4, 2025
- Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination Clinical Case Studies August 1, 2021
Cites 4
- Synaptic Dysfunction in Depression: Potential Therapeutic Targets Science October 4, 2012
- A REVIEW OF KETAMINE ABUSE AND DIVERSION Depression and Anxiety August 1, 2016
- KETAMINE: A POTENTIAL RAPID-ACTING ANTISUICIDAL AGENT? Depression and Anxiety April 15, 2016
- Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. The Journal of Clinical Psychiatry May 2015